Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents

Endocrinology and Metabolism Clinics of North America · Published 2026-05-28 · DOI 10.1016/j.ecl.2026.04.009

Authors (4)

Husam Ghanim, Sambasiva Rao Srungavarapu, Paresh Dandona, Ajay Chaudhuri

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Ghanim, H., Srungavarapu, S., Dandona, P., et al. (2026). Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2026.04.009

Related articles